The comparative evaluation of PSMA and GPC3—each with distinct biological rationales—will be critical in defining the optimal biomarker for HCC theranostics, particularly as we move toward personalized paradigms that integrate imaging phenotypes with molecular and histologic tumor characteristics. This evidence concerns the gene FOLH1 and neoplasm.